Veterinary Medicines

FEBRIVAC 3-PLUS

Not authorised
  • Clostridium botulinum, type C, strain Stockholm, toxoid
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
  • Mink enteritis virus, strain E-MINK F1, Inactivated
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
Download as PDF

Product identification

Medicine name:
FEBRIVAC 3-PLUS
Active substance:
  • Clostridium botulinum, type C, strain Stockholm, toxoid
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
  • Mink enteritis virus, strain E-MINK F1, Inactivated
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
Target species:
  • Mink
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Clostridium botulinum, type C, strain Stockholm, toxoid
    0.80
    80% Protective Dose
    /
    1.00
    millilitre(s)
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
    8.00
    Organisms
    /
    1.00
    millilitre(s)
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
    8.00
    Organisms
    /
    1.00
    millilitre(s)
  • Mink enteritis virus, strain E-MINK F1, Inactivated
    160.00
    haemagglutination inhibiting unit(s)
    /
    1.00
    millilitre(s)
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
    8.00
    Organisms
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI20CL01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Revoked
Authorised in:
  • Netherlands
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
  • IDT Biologika GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • IDT Biologika GmbH
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 9102
Date of authorisation status change: